Skip Navigation


Schizophrenia Bulletin Advance Access originally published online on March 11, 2008
Schizophrenia Bulletin 2008 34(3):403-405; doi:10.1093/schbul/sbn011
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
34/3/403    most recent
sbn011v2
sbn011v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Davis, J. M.
Right arrow Articles by Leucht, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, J. M.
Right arrow Articles by Leucht, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2008 The Authors
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Has Research Informed Us on the Practical Drug Treatment of Schizophrenia?

The first 10% of the full text of this article appears below.

Has the randomized controlled trial (RCT) research over the last 56 years (since antipsychotics were discovered) informed us of the central practical questions the clinician must face on how to medicate persons with schizophrenia? In this editorial, we will consider the degree to which RCT support practice in the following areas.

  1. Choice of drug and indication
  2. Dose
  3. Emergency treatment
  4. Monitoring treatment
  5. When to change drug or augment
  6. Depot medication
  7. Long-term changes and cost
  8. Progression
  9. Other considerations


   Choice of Drugs and Indication
 
We do not know the indication (which patient for which drug) for one antipsychotic versus another or even that one may be uniquely better for an individual patient. We have some information . . . [Full Text of this Article]


   Dose
 

   Emergency Treatment
 

   Monitoring Treatment
 

   When to Change Drug or Augment?
 

   Depot Medication
 

   Long-Term Changes and Cost
 

   Progression
 

   Other Considerations
 

John M. Davis13 and Stefan Leucht4
2 Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, 1601 W. Taylor Street, Room 508, Chicago, IL 60612
3 University of Maryland Psychiatric Research Center, Baltimore, MD
4 Klinik für Psychiatrie und Psychotherapie der TU-München, Ismaningerstr. 22, 81675 München, Germany

1 To whom correspondence should be addressed; tel: 312-413-4570, fax: 312-996-7658, e-mail: jdavis@psych.uic.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?